

List of Figures

Sr. No	Title	Page No.
Chapter 1		
Figure: 1.1	Anatomy of Skin	1
Figure 1.2	Detailed structure of epidermis	2
Figure 1.3	Epidermal Melanin Unit & Stages of Melanosomal maturation	3
Figure 1.4	Melanogenesis pathway	4
Figure 1.5	Clinical types of vitiligo	6
Figure 1.6	Prevalence of Vitiligo	7
Figure 1.7	Involvement of oxidative stress in development of vitiligo	10
Figure 1.8	Involvement of immunity in vitiligo	12
Figure 1.9	B7 Family members (Receptors and Ligands) and type of co-stimulation	14
Figure 1.10	Genomic and protein structure of VTCN1	16
Figure 1.11	Human VTCN1 structure as predicted by SWISS-model software	16
Figure 1.12	Hypothetical role of VTCN1 in vitiligo development and progression	25
Chapter 2		
Figure 2.1	PCR-RFLP analysis of <i>VTCN1</i> intronic polymorphisms on 3.5% agarose gel	51
Figure 2.2	<i>VTCN1</i> and <i>NRD1</i> transcript levels in PBMCs and skin of patients with Vitiligo and controls	60
Figure 2.3	Estimation of sVTCN1 and NRD1 levels in the plasma of patients with Vitiligo and controls	62
Figure 2.4	Correlation analysis of sVTCN1 with NRD1 levels in vitiligo individuals	63
Figure 2.5	Immunofluorescence analysis of control skin, non-lesional, perilesional, and lesional skin of vitiligo patients	64
Figure 2.6	VTCN1 in vitiligo pathogenesis	68
Chapter 3		
Figure 3.1	B7 family members and their receptors	75
Figure 3.2	Effect of VTCN1 upon binding with its receptor	75
Figure 3.3	Overall strategy for immunophenotyping	77
Figure 3.4	Gating strategy for subtyping of T cells into CD4 ⁺ , CD8 ⁺ T cells and regulatory T cells	81
Figure 3.5	Gating strategy for VTCN1 positive CD4, CD8 and regulatory T cells	82

Figure 3.6	Gating strategy for VTCN1 positive APC cells (Dendritic cells, B cells, Monocytes)	83
Figure 3.7	Immunophenotypic analysis of VTCN1 on different T cells from the blood of 25 generalized active vitiligo patients and 30 healthy controls	85
Figure 3.8	Immunophenotypic analysis of VTCN1 on activated T cells and Treg cells from the blood of 25 generalized active vitiligo patients and 30 healthy controls	86
Figure 3.9	Immunophenotypic analysis of VTCN1 on different APC (Antigen presenting cells) from the blood of 25 generalized active vitiligo patients and 30 healthy controls	87
Figure 3.10	Immunophenotypic analysis of VTCN1 on different T cells from the non lesional and lesional skin of 13 generalized active vitiligo patients and 10 healthy controls	89
Chapter 4		
Figure 4.1	Western blot analysis of pSTAT3, total-STAT3 and VTCN1 upon 50ng and 100ng of IFN γ for 24 hours	108
Figure 4.2	Western blot analysis of pSTAT3, total-STAT3 and VTCN1 upon 10ng and 20ng of TNF- α for 24 hours	109
Figure 4.3	Western blot analysis of pSTAT3, total-STAT3 and VTCN1 upon 10ng and 20ng of IL-10 for 24 hours	110
Conclusion		
Figure 5.1	Summary	120
Figure 5.2	Summary of immunophenotyping in vitiligo patients	121
Figure 5.3	Overall summary	122